STOCK TITAN

[8-K] Hims & Hers Health, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Hims & Hers Health, Inc. reported that on September 28, 2025 its Chief Operating Officer, Nader Kabbani, will move to an advisory role effective November 2, 2025 and will provide strategic guidance through July 2026. The company will promote Mike Chi, currently Chief Commercial Officer, to Chief Operating Officer effective on the Transition Date and will eliminate the separate Chief Commercial Officer role, consolidating operations, marketing, product, and commercial functions under Mr. Chi. Mr. Chi joined the company in April 2021 and has over 20 years of consumer internet experience. Compensation review by the Compensation Committee is planned; any changes require final approval.

Hims & Hers Health, Inc. ha riferito che il 28 settembre 2025 il suo Chief Operating Officer, Nader Kabbani, passerà in un ruolo di consulenza con efficacia 2 novembre 2025 e fornirà guida strategica fino a luglio 2026. L'azienda promuoverà Mike Chi, attualmente Chief Commercial Officer, a Chief Operating Officer effettivo alla Data di Transizione e eliminerà il ruolo separato di Chief Commercial Officer, consolidando operative, marketing, prodotto e funzioni commerciali sotto il Sig. Chi. Il Sig. Chi è entrato in azienda nell'aprile 2021 e vanta oltre 20 anni di esperienza nel settore internet per consumatori. Una revisione della retribuzione da parte del Compensation Committee è prevista; eventuali cambiamenti richiedono l'approvazione finale.

Hims & Hers Health, Inc. informó que el 28 de septiembre de 2025 su Director de Operaciones, Nader Kabbani, pasará a un rol de asesoría con eficacia 2 de noviembre de 2025 y brindará orientación estratégica hasta julio de 2026. La empresa promoverá a Mike Chi, actual Director Comercial, a Director de Operaciones efectivo en la Fecha de Transición y eliminará el rol separado de Director Comercial, consolidando operaciones, marketing, producto y funciones comerciales bajo el Sr. Chi. El Sr. Chi se unió a la empresa en abril de 2021 y cuenta con más de 20 años de experiencia en internet de consumo. Se planea una revisión de la compensación por parte del Comité de Compensación; cualquier cambio requiere aprobación final.

Hims & Hers Health, Inc.2025년 9월 28일에 최고운영책임자 Nader Kabbani2025년 11월 2일부로 고문 역할로 이동하고 2026년 7월까지 전략적 지도를 제공할 것이라고 발표했다. 회사는 현재 최고상무책임자 Mike Chi를 전환일에 최고운영책임자(COO)로 승격시키고, 별도의 최고상무책임자(CCO) 직위를 폐지하여 운영, 마케팅, 제품 및 상업 기능을 Chi 씨 아래로 통합한다. Chi 씨는 2021년 4월에 회사에 합류했으며 20년 이상의 소비자 인터넷 분야 경험을 보유하고 있다. 보상위원회에 의한 보상 검토가 예정되어 있으며, 변경사항은 최종 승인 필요.

Hims & Hers Health, Inc. a indiqué que le 28 septembre 2025 son Chief Operating Officer, Nader Kabbani, passera à un rôle de conseiller à compter du 2 novembre 2025 et offrira des conseils stratégiques jusqu’au juillet 2026. L’entreprise promouvra Mike Chi, actuellement Chief Commercial Officer, au poste de Chief Operating Officer à la date de transition et supprimera le rôle distinct de Chief Commercial Officer, consolidant les fonctions d’exploitation, de marketing, de produit et commerciales sous M. Chi. M. Chi a rejoint l’entreprise en avril 2021 et possède plus de 20 ans d’expérience dans l’internet grand public. Une révision de la rémunération par le Comité de rémunération est prévue; tout changement nécessite une approbation finale.

Hims & Hers Health, Inc. gab bekannt, dass sein Chief Operating Officer, Nader Kabbani, am 28. September 2025 in eine beratende Rolle wechseln wird, wirksam ab dem 2. November 2025, und bis Juli 2026 strategische Guidance leisten wird. Das Unternehmen wird Mike Chi, derzeit Chief Commercial Officer, zum Chief Operating Officer befördern, wirksam am Übergabe-/Transition-Datum, und die separate Rolle des Chief Commercial Officer abschaffen, wodurch die Funktionen Betrieb, Marketing, Produkt und kommerzielle Funktionen unter Herrn Chi konsolidiert werden. Herr Chi trat im April 2021 in das Unternehmen ein und verfügt über mehr als 20 Jahre Erfahrung im Bereich des Consumer Internet. Eine Vergütungsüberprüfung durch den Vergütungsausschuss ist vorgesehen; Änderungen bedürfen der endgültigen Genehmigung.

Hims & Hers Health, Inc. ذكرت أنه في 28 سبتمبر 2025 سينتقل رئيس العمليات التنفيذي، نادر قاباني، إلى دور استشاري اعتباراً من 2 نوفمبر 2025 وسيقدم إرشاداً استراتيجياً حتى يوليو 2026. ستقوم الشركة بترقية مايك تشي، حالياً المدير التنفيذي التجاري، إلى الرئيس التنفيذي للعمليات اعتباراً من تاريخ الانتقال وستلغي دور الرئيس التنفيذي التجاري المنفصل، مما يوحد عمليات التشغيل والتسويق والمنتج والوظائف التجارية تحت السيد تشي. انضم السيد تشي إلى الشركة في أبريل 2021 ولديه أكثر من 20 عاماً من الخبرة في الإنترنت الاستهلاكي. من المقرر إجراء مراجعة جيو/تعويضات من قبل لجنة التعويضات؛ أي تغييرات تتطلب موافقة نهائية.

Hims & Hers Health, Inc. 报告称,其首席运营官 Nader Kabbani 将于 2025年9月28日 转任顾问角色,生效日期为 2025年11月2日,并将提供直至 2026年7月 的战略指导。公司将晋升 Mike Chi,当前的首席商业官,成为过渡日期生效的首席运营官,并将取消单独的首席商业官职位,在 Chi 先生之下合并运营、营销、产品和商业职能。Chi 先生于 2021年4月 加入公司,拥有超过 20 年的消费互联网经验。薪酬委员会计划进行薪酬复核;任何变动需获得最终批准。

Positive
  • Seamless succession plan with outgoing COO remaining as advisor through July 2026
  • Consolidation of operations, marketing, product, and commercial functions under one executive could improve coordination
  • Mike Chi brings 20+ years of relevant consumer internet and marketing experience and has been with the company since April 2021
Negative
  • Elimination of the Chief Commercial Officer role concentrates responsibilities and may create execution risk if not supported
  • Compensation changes for Mr. Chi are under review and not yet finalized, introducing short-term uncertainty about costs

Insights

Officer transition centralizes operations under an experienced marketing and product leader.

The appointment of Mike Chi as COO consolidates operations, marketing, product, and commercial functions, which may streamline decision-making and execution for those areas.

The outgoing COO, Nader Kabbani, shifts to an advisory role through July 2026, preserving continuity while enabling a formal transition.

Hims & Hers Health, Inc. ha riferito che il 28 settembre 2025 il suo Chief Operating Officer, Nader Kabbani, passerà in un ruolo di consulenza con efficacia 2 novembre 2025 e fornirà guida strategica fino a luglio 2026. L'azienda promuoverà Mike Chi, attualmente Chief Commercial Officer, a Chief Operating Officer effettivo alla Data di Transizione e eliminerà il ruolo separato di Chief Commercial Officer, consolidando operative, marketing, prodotto e funzioni commerciali sotto il Sig. Chi. Il Sig. Chi è entrato in azienda nell'aprile 2021 e vanta oltre 20 anni di esperienza nel settore internet per consumatori. Una revisione della retribuzione da parte del Compensation Committee è prevista; eventuali cambiamenti richiedono l'approvazione finale.

Hims & Hers Health, Inc. informó que el 28 de septiembre de 2025 su Director de Operaciones, Nader Kabbani, pasará a un rol de asesoría con eficacia 2 de noviembre de 2025 y brindará orientación estratégica hasta julio de 2026. La empresa promoverá a Mike Chi, actual Director Comercial, a Director de Operaciones efectivo en la Fecha de Transición y eliminará el rol separado de Director Comercial, consolidando operaciones, marketing, producto y funciones comerciales bajo el Sr. Chi. El Sr. Chi se unió a la empresa en abril de 2021 y cuenta con más de 20 años de experiencia en internet de consumo. Se planea una revisión de la compensación por parte del Comité de Compensación; cualquier cambio requiere aprobación final.

Hims & Hers Health, Inc.2025년 9월 28일에 최고운영책임자 Nader Kabbani2025년 11월 2일부로 고문 역할로 이동하고 2026년 7월까지 전략적 지도를 제공할 것이라고 발표했다. 회사는 현재 최고상무책임자 Mike Chi를 전환일에 최고운영책임자(COO)로 승격시키고, 별도의 최고상무책임자(CCO) 직위를 폐지하여 운영, 마케팅, 제품 및 상업 기능을 Chi 씨 아래로 통합한다. Chi 씨는 2021년 4월에 회사에 합류했으며 20년 이상의 소비자 인터넷 분야 경험을 보유하고 있다. 보상위원회에 의한 보상 검토가 예정되어 있으며, 변경사항은 최종 승인 필요.

Hims & Hers Health, Inc. a indiqué que le 28 septembre 2025 son Chief Operating Officer, Nader Kabbani, passera à un rôle de conseiller à compter du 2 novembre 2025 et offrira des conseils stratégiques jusqu’au juillet 2026. L’entreprise promouvra Mike Chi, actuellement Chief Commercial Officer, au poste de Chief Operating Officer à la date de transition et supprimera le rôle distinct de Chief Commercial Officer, consolidant les fonctions d’exploitation, de marketing, de produit et commerciales sous M. Chi. M. Chi a rejoint l’entreprise en avril 2021 et possède plus de 20 ans d’expérience dans l’internet grand public. Une révision de la rémunération par le Comité de rémunération est prévue; tout changement nécessite une approbation finale.

Hims & Hers Health, Inc. gab bekannt, dass sein Chief Operating Officer, Nader Kabbani, am 28. September 2025 in eine beratende Rolle wechseln wird, wirksam ab dem 2. November 2025, und bis Juli 2026 strategische Guidance leisten wird. Das Unternehmen wird Mike Chi, derzeit Chief Commercial Officer, zum Chief Operating Officer befördern, wirksam am Übergabe-/Transition-Datum, und die separate Rolle des Chief Commercial Officer abschaffen, wodurch die Funktionen Betrieb, Marketing, Produkt und kommerzielle Funktionen unter Herrn Chi konsolidiert werden. Herr Chi trat im April 2021 in das Unternehmen ein und verfügt über mehr als 20 Jahre Erfahrung im Bereich des Consumer Internet. Eine Vergütungsüberprüfung durch den Vergütungsausschuss ist vorgesehen; Änderungen bedürfen der endgültigen Genehmigung.

0001773751false00017737512025-09-282025-09-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________________________________________________________

FORM 8-K
_____________________________________________________________________________________________________________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2025
_____________________________________________________________________________________________________________________

HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
_____________________________________________________________________________________________________________________

Delaware 001-38986 98-1482650
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
2269 Chestnut Street, #523
San Francisco, CA 94123
(Address of principal executive offices)
(415) 851-0195
(Registrant’s telephone number, including area code)
______________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Class A Common Stock, $0.0001 par value HIMS New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  





Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On September 28, 2025, Nader Kabbani, the Chief Operating Officer of Hims & Hers Health, Inc. (the “Company”) determined to step into a new advisory role for the Company effective November 2, 2025 (the “Transition Date”), where he will continue to provide ongoing strategic guidance to the Company and support for special global initiatives through July 2026. In connection with such transition, the Company will elevate Mike Chi, who currently serves as the Company’s Chief Commercial Officer, to the role of Chief Operating Officer, and will consolidate the operations, marketing, product, and commercial functions under Mr. Chi. Mr. Chi will be appointed as the Company’s Chief Operating Officer effective as of the Transition Date, and the Company will not have a separate Chief Commercial Officer.

Mr. Chi, 46, joined the Company in April 2021. He oversees marketing, product management, category management and international. Mr. Chi brings over 20 years of experience in consumer internet across growth marketing, brand positioning, product management, merchandising and strategy. Prior to joining the Company, Mr. Chi was the Chief Marketing Officer at Zola, a suite of digital wedding planning tools, from June 2017 through April 2021, where he led all aspects of the company’s marketing, creative and communications as well as acting as GM for the company’s planning tools. He was Vice President of Marketing and Ecommerce for INTERMIX, a luxury fashion retailer, from September 2015 through June 2017, leading marketing, creative, product management and e-commerce operations. Mr. Chi was also SVP, General Manager Women’s at Gilt Groupe, an online shopping and lifestyle company, from October 2010 through September 2015. Prior to his tenure at Gilt, Mr. Chi served in various roles at Boston Consulting Group, the Children’s Place and Gap Inc. He holds an M.B.A. from Columbia Business School and a B.A. from Brown University.

Mr. Chi’s current compensation is described in the “Executive Compensation” section in the Company’s definitive proxy statement, filed with the SEC on April 25, 2025. The Company’s Compensation Committee plans to review and evaluate potential changes to Mr. Chi’s compensation arrangements in light of his new and increased responsibilities in connection with his anticipated transition to Chief Operating Officer. Any changes to compensation will be subject to final determination and approval of the Compensation Committee upon completion of such review. Mr. Chi is also party to the Company’s standard form of indemnification agreement and standard form of change in control and severance agreement.

There are no arrangements or understandings between Mr. Chi and any other person pursuant to which he was appointed as an officer of the Company. There are no family relationships between Mr. Chi and any director, executive officer, or any person nominated or chosen by the Company to become a director or executive officer. Mr. Chi is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K.






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HIMS & HERS HEALTH, INC.
Date: October 2, 2025
By:
/s/ Andrew Dudum
Andrew Dudum
Chief Executive Officer


FAQ

What change did HIMS report in the 8-K?

The company reported that COO Nader Kabbani will move to an advisory role effective November 2, 2025, and Mike Chi will become COO on that date.

How long will the outgoing COO remain involved with HIMS?

Mr. Kabbani will provide strategic guidance and support for special global initiatives through July 2026.

What responsibilities will the new COO have?

Mr. Chi will consolidate and oversee operations, marketing, product, and commercial functions.

When did Mike Chi join HIMS and what is his background?

Mr. Chi joined in April 2021 and has over 20 years of consumer internet experience, including senior roles at Zola, INTERMIX, and Gilt Groupe.

Will Mr. Chi’s compensation change with the new role?

The Compensation Committee plans to review his compensation; any changes require final committee approval.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

12.73B
193.66M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO